AbCellera — Q3 2026 Earnings Summary

AbCellera reported a net loss of $40.8 million for the third quarter of 2026, a reduction from the $57.1 million loss in the same period of 2025, while total revenue increased to $10.6 million. The company completed a $200 million capital offering, bringing its total available liquidity to approximately $890 million. Clinical updates included positive Phase 2 results for ABCL635 in treating vasomotor symptoms and a successful Phase 1 readout for ABCL575, which is not planned for further development. Additionally, AbCellera advanced three new antibody drug candidates, ABCL992, ABCL385, and ABCL646, into IND-enabling activities.